Cadrenal Therapeutics(us:CVKD)
16.17
+11.59%
Updated on 2024-12-22
Open:15.89
Close:16.17
High:18.00
Low:15.33
Pre Close:14.49
Volume:202023.00
Amount:3.38M
Turnover:11.33%
Shares:1.78M
MarketCap:28.82M
About Cadrenal Therapeutics Company
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Company Name: Cadrenal Therapeutics
Company Address: 822 A1A North,Suite 306
Employees: 4
Fiscar Year: 12-31
IPO Date: 2023-01-20
Website: http://www.cadrenal.com
CIK: 1937993
View all SEC Filings
About
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Address:822 A1A North,Suite 306
Website:http://www.cadrenal.com
Market Movers